 Basking Ridge, NJ, Oct. 07, 2021 GLOBE NEWSWIRE -- via NewMediaWire -- Timber Pharmaceuticals, Inc. Timber or the Company NYSE American: TMBR, a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced positive top-line data from its Phase 2b CONTROL study evaluating TMB-001, an investigational topical isotretinoin formulated using Timbers patented IPEGTM delivery system, in patients with moderate to severe congenital ichthyosis CI. 